Impeto Medical   Report issue

For profit Phase 3
Founded: Paris France (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2014
NCT03050827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

oxybutynin (ditropan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 3)

Polyneuropathies (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1